deferoxamine has been researched along with Alzheimer Disease in 48 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 6.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| " Herein, we discuss the various dosing regimens and formulations employed in intranasal (IN) or systemic DFO treatment, as well as the physiological and behavioral outcomes observed in animal models of AD, PD, and ICH." | 2.72 | Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. ( Farr, AC; Xiong, MP, 2021) |
| " Presence of drug in the olfactory bulb, in turn, increases the drug bioavailability in the brain and reduces the drug degradation as well as wastage of the drug through` systemic clearance." | 2.58 | Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. ( Agrawal, M; Alexander, A; Antimisiaris, SG; Chougule, MB; Saraf, S; Shoyele, SA, 2018) |
| " Highlighted are insights to be considered in the quests to prevent potentially toxic effects of aluminum toxicity and prevention and intervention in AD." | 2.47 | Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. ( Kruck, TP; Lukiw, WJ; Percy, ME; Pogue, AI, 2011) |
| " An understanding of a possible enhanced bioavailability of Al in this type of exposure, versus other exposures such as antacid intake or industrial exposure, needs to be considered and explored." | 2.39 | Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered? ( Exley, C; Forbes, WF; Huang, Y; Joshi, JG; Kruck, T; McLachlan, DR; Savory, J; Wakayama, I, 1996) |
| "Over 44 million people live with Alzheimer's disease (AD) worldwide." | 1.46 | A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease. ( Anjum, R; Bernhardt, PV; Hibbs, D; Kalinowski, DS; Lin, HY; Palanimuthu, D; Poon, R; Richardson, DR; Sahni, S, 2017) |
| "Deferoxamine (DFO) is a metal chelator found to be beneficial in several animal models of neurodegenerative disease and insult including Alzheimer's disease, Parkinson's disease, stroke, and subarachnoid hemorrhage." | 1.46 | Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease. ( Crow, JM; Faltesek, KA; Fine, JM; Forsberg, AC; Frey, WH; Haase, LR; Hamel, KA; Hanson, LR; Kaczmarczek, KD; Knutzen, KE; Raney, EB; Stroebel, BM; Verden, DR, 2017) |
| " Iron is an essential nutrient but high levels are toxic due to the catalytic generation of destructive hydroxyl radicals." | 1.43 | A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity. ( Cahill, CM; Jiang, H; Liu, Y; Rogers, JT; Smith, A; Tummala, V; Venkataramani, V; Washburn, C, 2016) |
| "Pretreatment with deferoxamine or diethylenetriaminepentaacetic acid abolishes the ability of the lesions to catalyze the H2O2-dependent oxidation of 3,3'-diaminobenzidine (DAB), strongly suggesting the involvement of associated transition metal ions." | 1.31 | In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. ( Harris, PL; Liu, Y; Perry, G; Sayre, LM; Schubert, KA; Smith, MA, 2000) |
| "A clinical trial in patients with Alzheimer's disease has indicated that frequent intramuscular (i." | 1.30 | Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease. ( Herman, MM; Huang, Y; Savory, J; Wills, MR, 1998) |
| "Deferoxamine treatment may produce serious side effects that can be eliminated by modification of treatment and by control of deferoxamine metabolism." | 1.28 | Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation. ( Fisher, EA; Kruck, TP; McLachlan, DR, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.42) | 18.7374 |
| 1990's | 10 (20.83) | 18.2507 |
| 2000's | 10 (20.83) | 29.6817 |
| 2010's | 18 (37.50) | 24.3611 |
| 2020's | 5 (10.42) | 2.80 |
| Authors | Studies |
|---|---|
| Palanimuthu, D | 1 |
| Poon, R | 1 |
| Sahni, S | 1 |
| Anjum, R | 1 |
| Hibbs, D | 1 |
| Lin, HY | 1 |
| Bernhardt, PV | 1 |
| Kalinowski, DS | 1 |
| Richardson, DR | 1 |
| Soleimani Asl, S | 1 |
| Gharebaghi, A | 1 |
| Shahidi, S | 1 |
| Afshar, S | 1 |
| Kalhori, F | 1 |
| Amiri, K | 1 |
| Mirzaei, F | 1 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 4 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Kwan, P | 1 |
| Ho, A | 1 |
| Baum, L | 1 |
| Farr, AC | 1 |
| Xiong, MP | 1 |
| Cilliers, K | 1 |
| Fine, JM | 3 |
| Forsberg, AC | 2 |
| Stroebel, BM | 2 |
| Faltesek, KA | 1 |
| Verden, DR | 1 |
| Hamel, KA | 1 |
| Raney, EB | 1 |
| Crow, JM | 1 |
| Haase, LR | 1 |
| Knutzen, KE | 1 |
| Kaczmarczek, KD | 1 |
| Frey, WH | 3 |
| Hanson, LR | 3 |
| Zhang, Y | 1 |
| He, ML | 1 |
| Agrawal, M | 1 |
| Saraf, S | 2 |
| Antimisiaris, SG | 1 |
| Chougule, MB | 1 |
| Shoyele, SA | 1 |
| Alexander, A | 1 |
| Hernández-Sánchez, A | 1 |
| Tejada-González, P | 1 |
| Arteta-Jiménez, M | 1 |
| Di Lorenzo, F | 1 |
| Di Lorenzo, B | 1 |
| Renner, DB | 2 |
| Cameron, RA | 1 |
| Galick, BT | 1 |
| Le, C | 1 |
| Conway, PM | 1 |
| Meadowcroft, MD | 1 |
| Peters, DG | 1 |
| Dewal, RP | 1 |
| Connor, JR | 1 |
| Yang, QX | 1 |
| Cheng, F | 1 |
| Bourseau-Guilmain, E | 1 |
| Belting, M | 1 |
| Fransson, LÅ | 1 |
| Mani, K | 1 |
| Rogers, JT | 2 |
| Venkataramani, V | 1 |
| Washburn, C | 1 |
| Tummala, V | 1 |
| Jiang, H | 1 |
| Smith, A | 1 |
| Cahill, CM | 2 |
| Schubert, D | 2 |
| Soucek, T | 1 |
| Blouw, B | 1 |
| Liu, G | 1 |
| Men, P | 1 |
| Perry, G | 2 |
| Smith, MA | 2 |
| Esparza, JL | 1 |
| Garcia, T | 1 |
| Gómez, M | 1 |
| Nogués, MR | 1 |
| Giralt, M | 1 |
| Domingo, JL | 1 |
| Lee, JS | 1 |
| Park, CB | 1 |
| Ill-Raga, G | 1 |
| Ramos-Fernández, E | 1 |
| Guix, FX | 1 |
| Tajes, M | 1 |
| Bosch-Morató, M | 1 |
| Palomer, E | 1 |
| Godoy, J | 1 |
| Belmar, S | 1 |
| Cerpa, W | 1 |
| Simpkins, JW | 1 |
| Inestrosa And, NC | 1 |
| Muñoz, FJ | 1 |
| Percy, ME | 1 |
| Kruck, TP | 9 |
| Pogue, AI | 1 |
| Lukiw, WJ | 1 |
| Baillargeon, AM | 1 |
| Hoerster, NS | 1 |
| Tokarev, J | 1 |
| Colton, S | 1 |
| Pelleg, A | 1 |
| Andrews, A | 1 |
| Sparley, KA | 1 |
| Krogh, KM | 1 |
| Guo, C | 2 |
| Wang, T | 2 |
| Zheng, W | 1 |
| Shan, ZY | 1 |
| Teng, WP | 1 |
| Wang, ZY | 2 |
| Wang, P | 1 |
| Zhong, ML | 1 |
| Huang, XS | 1 |
| Li, JY | 1 |
| Randall, JD | 1 |
| Eder, PS | 1 |
| Huang, X | 1 |
| Gunshin, H | 1 |
| Leiter, L | 1 |
| McPhee, J | 1 |
| Sarang, SS | 1 |
| Utsuki, T | 1 |
| Greig, NH | 1 |
| Lahiri, DK | 1 |
| Tanzi, RE | 1 |
| Bush, AI | 2 |
| Giordano, T | 1 |
| Gullans, SR | 1 |
| Shin, RW | 2 |
| Murayama, H | 2 |
| Kitamoto, T | 2 |
| Finefrock, AE | 1 |
| Doraiswamy, PM | 1 |
| Mahlapuu, R | 1 |
| Viht, K | 1 |
| Balaspiri, L | 1 |
| Bogdanovic, N | 3 |
| Saar, K | 1 |
| Soomets, U | 1 |
| Land, T | 3 |
| Zilmer, M | 1 |
| Karelson, E | 3 |
| Langel, U | 1 |
| Fernaeus, S | 1 |
| Reis, K | 2 |
| Zharkovsky, A | 1 |
| Shore, D | 1 |
| Wyatt, RJ | 1 |
| Chevion, M | 1 |
| McLachlan, DR | 7 |
| Smith, WL | 2 |
| Kumar, U | 1 |
| Dunlop, DM | 1 |
| Richardson, JS | 1 |
| Fisher, EA | 2 |
| Savory, J | 2 |
| Exley, C | 1 |
| Forbes, WF | 1 |
| Huang, Y | 2 |
| Joshi, JG | 1 |
| Kruck, T | 1 |
| Wakayama, I | 1 |
| Wills, MR | 1 |
| Herman, MM | 1 |
| Higuchi, J | 1 |
| Shibuya, S | 1 |
| Muramoto, T | 1 |
| Sayre, LM | 1 |
| Harris, PL | 1 |
| Schubert, KA | 1 |
| de la Monte, SM | 1 |
| Neely, TR | 1 |
| Cannon, J | 1 |
| Wands, JR | 1 |
| Monji, A | 1 |
| Utsumi, H | 1 |
| Ueda, T | 1 |
| Imoto, T | 1 |
| Yoshida, I | 1 |
| Hashioka, S | 1 |
| Tashiro, K | 1 |
| Tashiro, N | 1 |
| Crapper McLachlan, DR | 1 |
| Dalton, AJ | 1 |
| Bell, MY | 1 |
| Kalow, W | 2 |
| Andrews, DF | 1 |
| VanBerkum, MF | 1 |
| King, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An N of One Clinical Trial to Pilot the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment[NCT02878538] | Early Phase 1 | 0 participants (Actual) | Interventional | 2018-01-31 | Withdrawn (stopped due to Study was withdrawn before IRB approval) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for deferoxamine and Alzheimer Disease
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2021 |
Trace element alterations in Alzheimer's disease: A review.
Topics: Alzheimer Disease; Clioquinol; Copper; Deferoxamine; Humans; Metals; Penicillamine; Siderophores; Tr | 2021 |
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Blood-Brain Barrier | 2018 |
Aluminium in parenteral nutrition: a systematic review.
Topics: Aluminum; Alzheimer Disease; Bone Diseases, Metabolic; Deferoxamine; Dyslipidemias; Humans; Iron; Ke | 2013 |
Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Deferoxamine; Environmenta | 2011 |
Current status of metals as therapeutic targets in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Chelating Agents; Clioquinol; Copper; Deferoxamin | 2003 |
Aluminum and Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Animals; Brain Chemistry; Cell Nucleus; Cooking and Eating Utensils; De | 1983 |
Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
Topics: Aluminum; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Deferoxamine; Environmental Ex | 1996 |
Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion specific chelation.
Topics: Aluminum; Alzheimer Disease; Animals; Brain; Chelating Agents; Deferoxamine; Environmental Exposure; | 1989 |
Aluminum and neurodegenerative disease: therapeutic implications.
Topics: Aluminum; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Calcium; Deferoxamine; D | 1985 |
3 trials available for deferoxamine and Alzheimer Disease
| Article | Year |
|---|---|
Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
Topics: Aged; Aluminum; Alzheimer Disease; Behavior; Brain Chemistry; Deferoxamine; Female; Humans; Male; Mi | 1993 |
A predictor for side effects in patients with Alzheimer's disease treated with deferoxamine mesylate.
Topics: Alzheimer Disease; Anorexia; Chromatography, High Pressure Liquid; Deferoxamine; Female; Humans; Inj | 1993 |
Intramuscular desferrioxamine in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Chromatography, High Pressure Liquid; Deferoxamine; F | 1991 |
34 other studies available for deferoxamine and Alzheimer Disease
| Article | Year |
|---|---|
A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relation | 2017 |
Deferoxamine preconditioning enhances the protective effects of stem cells in streptozotocin-induced Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Survival; Cells, Cultured; Deferoxamine; Dose-Response Relationship | 2021 |
Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models.
Topics: Alzheimer Disease; Animals; Deferasirox; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Ch | 2022 |
Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Blood Glucose; | 2017 |
Deferoxamine enhances alternative activation of microglia and inhibits amyloid beta deposits in APP/PS1 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cognition; Deferoxamine; Disease Model | 2017 |
Iron and aluminum in Alzheimer's disease.
Topics: Aged; Aluminum; Alzheimer Disease; Antioxidants; Ascorbic Acid; Chelation Therapy; Deferoxamine; Epi | 2013 |
Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Animals; bet | 2015 |
The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Deferoxamine; Humans; Iron; Magnetic Resonance Imagin | 2015 |
Hypoxia induces NO-dependent release of heparan sulfate in fibroblasts from the Alzheimer mouse Tg2576 by activation of nitrite reduction.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal; Ascorbic Acid; Cell Hypoxia; Deferoxamine; Disea | 2016 |
A role for amyloid precursor protein translation to restore iron homeostasis and ameliorate lead (Pb) neurotoxicity.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Deferoxamine; Gene Expression Regulation; Homeost | 2016 |
The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cells, Cultured; Deferoxamine; Glucos | 2009 |
Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
Topics: Aged; Alzheimer Disease; Benzoates; Blood-Brain Barrier; Brain; Chelation Therapy; Deferasirox; Defe | 2010 |
Role of deferoxamine on enzymatic stress markers in an animal model of Alzheimer's disease after chronic aluminum exposure.
Topics: Aluminum; Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Brain; Brain Chemistry; Che | 2011 |
Microfluidic dissociation and clearance of Alzheimer's beta-amyloid aggregates.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Deferoxamine; Humans; Iron; Iron Chel | 2010 |
Amyloid-β peptide fibrils induce nitro-oxidative stress in neuronal cells.
Topics: Aged; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Caspase 3 | 2010 |
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Deferoxamine; Glycogen Synthase Kinas | 2012 |
Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, An | 2013 |
Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Deferoxamine; Hippoca | 2013 |
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.
Topics: 5' Untranslated Regions; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Base Sequence; | 2002 |
A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Brain; Chelating Agents; Deferoxamine; Humans; Immunoblotting; Iron; Mo | 2003 |
Amyloid precursor protein carboxy-terminal fragments modulate G-proteins and adenylate cyclase activity in Alzheimer's disease brain.
Topics: Acetylcysteine; Adenylyl Cyclases; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Protein | 2003 |
Stimulation of G-proteins in human control and Alzheimer's disease brain by FAD mutants of APP(714-723): implication of oxidative mechanisms.
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Antioxidants; Cell Membrane; Cerebral Corte | 2005 |
Critical role of methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723).
Topics: Aged; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Case-Control Studies; Cell Differe | 2007 |
The role of iron in beta amyloid toxicity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cell Survival; Cells, Cultured; Cereb | 1995 |
Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Calcium; Deferoxamine; Fibroblasts; Free Radicals | 1994 |
Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Animals; Brain; Deferoxamine; Male; Neurofibrillary Tangles; Organometa | 1998 |
Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method.
Topics: Aluminum; Alzheimer Disease; Antibodies, Monoclonal; Chelating Agents; Deferoxamine; Epitopes; Flavo | 1999 |
In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals.
Topics: 3,3'-Diaminobenzidine; Aged; Aged, 80 and over; Alzheimer Disease; Catalysis; Chelating Agents; Copp | 2000 |
Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Division; Cell Hypoxia; Cell Survival; Cells, Cultured; | 2000 |
Amyloid-beta-protein (A beta) (25-35)-associated free radical generation is strongly influenced by the aggregational state of the peptides.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cyclic N-Oxides; Deferoxamine; Drug Antagonism; E | 2002 |
Desferrioxamine for Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Deferoxamine; Drinking; Humans | 1991 |
Suppression of deferoxamine mesylate treatment-induced side effects by coadministration of isoniazid in a patient with Alzheimer's disease subject to aluminum removal by ionspecific chelation.
Topics: Aluminum; Alzheimer Disease; Chelation Therapy; Chromatography, High Pressure Liquid; Deferoxamine; | 1990 |
Determination of desferoxamine and a major metabolite by high-performance liquid chromatography. Application to the treatment of aluminium-related disorders.
Topics: Aluminum; Alzheimer Disease; Chelating Agents; Chromatography, High Pressure Liquid; Deferoxamine; F | 1985 |
Desferrioxamine and Alzheimer's dementia.
Topics: Alzheimer Disease; Animals; Deferoxamine; Disease Models, Animal; Humans; Rabbits | 1985 |